Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mi | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
Mo | CANTOR FITZGERALD REITERATES ELUTIA STOCK RATING WITH $7 TARGET | 2 | Investing.com | ||
28.05. | Elutia Inc.: Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro Testing Method | 1 | GlobeNewswire (USA) | ||
13.05. | ELUTIA INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
06.05. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
01.05. | Elutia Inc.: Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio | 64 | GlobeNewswire (Europe) | Move expected to drive both top-line growth and gross margin improvement SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting... ► Artikel lesen | |
01.05. | Elutia Inc.: Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025 | 1 | GlobeNewswire (USA) | ||
ELUTIA Aktie jetzt für 0€ handeln | |||||
21.04. | Elutia Inc.: Elutia Initiates EluPro Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice | 1 | GlobeNewswire (USA) | ||
04.04. | Elutia Inc.: EluPro Named as 2025 Edison Award Winner | 2 | GlobeNewswire (USA) | ||
27.03. | Elutia Inc.: Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro | 2 | GlobeNewswire (USA) | ||
25.03. | Elutia Inc.: Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope | 1 | GlobeNewswire (USA) | ||
17.03. | Elutia stock soars, Anteris falls in medical devices sector | 4 | Investing.com | ||
11.03. | ELUTIA INC. - 10-K, Annual Report | 1 | SEC Filings | ||
10.03. | Cantor Fitzgerald keeps Aziyo Biologics stock at $8 target | 1 | Investing.com | ||
07.03. | Cantor Fitzgerald maintains $8 target on Aziyo Biologics stock | 1 | Investing.com | ||
06.03. | Elutia Inc. Q4 Loss Decreases | - | RTTNews | ||
06.03. | Elutia Inc.: Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro in Pilot Launch Sets the Stage for Full Commercial Roll-Out | 68 | GlobeNewswire (Europe) | - Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization - SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia"... ► Artikel lesen | |
06.03. | ELUTIA INC. - 8-K, Current Report | - | SEC Filings | ||
20.02. | Elutia Inc.: Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025 | 1 | GlobeNewswire (USA) | ||
03.02. | Elutia launches $15M securities offering | 3 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SPRINGWORKS THERAPEUTICS | 46,710 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 34,220 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 15,520 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
ARCELLX | 65,48 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 28,880 | 0,00 % | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | ||
BIONTECH | 98,90 | +1,44 % | Rheinmetall nicht zu bremsen! Evotec LEERVERKAUFT! Paukenschlag bei Vidac Pharma! Und was macht BioNTech Aktie? | Paukenschlag bei Vidac Pharma. Der Biotech-Highflyer des vergangenen Jahres hat starke Ergebnisse zu seinem Krebsmedikament veröffentlicht. Um 5 % ging es immerhin gestern nach oben. Ist die Konsolidierung... ► Artikel lesen | |
ENLIVEN THERAPEUTICS | 22,290 | 0,00 % | Mizuho erhöht Kursziel für Enliven Therapeutics-Aktie auf 41 US-Dollar | ||
DISC MEDICINE | 47,320 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update | Company remains on track to submit NDA for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025Initiated APOLLO, a confirmatory clinical trial of bitopertin in adults and adolescents with... ► Artikel lesen | |
APOGEE THERAPEUTICS | 36,500 | 0,00 % | Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results | Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in... ► Artikel lesen | |
ADMA BIOLOGICS | 20,330 | -0,64 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
QIAGEN | 40,320 | -0,01 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Qiagen mit einem Kursziel von 48 Euro auf "Buy" belassen. Der Tenor auf der Berenberg-MedTech-Investorenkonferenz in Manhatten... ► Artikel lesen | |
89BIO | 10,050 | 0,00 % | 89bio hält Jahreshauptversammlung ab, Direktoren gewählt | ||
ARCUTIS BIOTHERAPEUTICS | 13,260 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung und 19 US-Dollar Kursziel für Arcutis-Aktie | ||
KYMERA THERAPEUTICS | 44,310 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen | |
FULCRUM THERAPEUTICS | 7,030 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics to Present at Upcoming Medical Meetings |